Table 1.

Characteristics of the seven selected studies

Author/year [Ref.]	Line of treatment	Bevacizumab dose	No. of patients	Median PFS (m)	Median OS (m)	ORR (%)
				HTN vs. No HTN	HTN vs. No HTN	HTN vs. No HTN
Scartozzi M/2009 [20]	First-line	5 mg/kg/2w	39	14.5 vs. 3.1	NA vs. 15.1	75% vs. 32%
Rebekah/2009 [21]	First-line	NA	52	NA vs. NA	NA vs. NA	NA vs. NA
De Stefano/2011 [19]	First-line	5 mg/kg/2w or 7.5 mg/kg/3w	74	15.1 vs. 8.3	35.5 vs. 26.7	84.6% vs. 42.6%
Osterlund P/2011 [17]	First- or second-line	5 mg/kg/2w	101	10.5 vs. 5.3	25.8 vs. 11.7	52.6% vs. 45.5%
Horinouchi Y/2011 [18]	First-line	NA	36	16.25 vs. 10	NA vs. NA	60% vs. 23.1%
Dewdney A/2011 [22]	First-line	7.5 mg/kg/3w	45	NA vs. NA	NA vs. NA	71% vs. 78%
Tahover E/2013 [16]	First- or second-line	2. 5 mg/kg/w	181	29.9 vs. 17.2	NA vs. 36.8	NA vs. NA

ORR: Overall response rate; NA: Information not available; PFS: Progression-free survival; OS: Overall survival; HTN: Hypertension group; N0 HTN: No hypertension.